Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-39,900
Closed -$7.02M 2911
2025
Q4
$7.02M Buy
39,900
+38,300
+2,394% +$6.26M 0.01% 1212
2025
Q3
$224K Buy
+1,600
New +$216K ﹤0.01% 2692
2024
Q4
Sell
-6,400
Closed -$1.24M 2746
2024
Q3
$1.24M Buy
+6,400
New +$1.34M ﹤0.01% 1875
2020
Q2
Sell
-90,000
Closed -$28.5M 1135
2020
Q1
$28.5M Buy
+90,000
New +$27.3M 0.34% 69
2018
Q4
Sell
-57,000
Closed -$19.3M 1409
2018
Q3
$19.3M Buy
+57,000
New +$19.6M 0.09% 309
2017
Q1
Sell
-90,000
Closed -$23.5M 1589
2016
Q4
$23.5M Buy
+90,000
New +$26.7M 0.13% 227
2016
Q1
Sell
-25,000
Closed -$7.66M 1276
2015
Q4
$7.66M Buy
+25,000
New +$7.18M 0.05% 417
2015
Q1
Sell
-29,600
Closed -$10M 944
2014
Q4
$10M Buy
+29,600
New +$9.58M 0.09% 297

Other funds holding BIIB

Dmitry Balyasny's BIIB Position: Q2 2026 in Review

Dmitry Balyasny reduced its Biogen (BIIB) stake by 59% in Q2 2026, selling an estimated $73.6M and leaving 265,090 shares worth $57.3M. The position accounts for 0.07% of the portfolio, ranked #323.

Dmitry Balyasny first reported a position in BIIB in Q4 2014 and has held it in 43 quarters since. The position peaked at $174M in Q4 2017. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Dmitry Balyasny held 265,090 shares of Biogen worth $57.3M as of Q2 2026.
  • Dmitry Balyasny sold 384,956 Biogen shares in Q2 2026, an estimated $73.6M.
  • Biogen made up 0.07% of Dmitry Balyasny's portfolio in Q2 2026, its #323 holding.
  • Dmitry Balyasny first reported a position in Biogen in Q4 2014 and has held it in 43 quarters since.
  • Dmitry Balyasny's Biogen position peaked at $174M in Q4 2017.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.